iRhythm Technologies (NASDAQ:IRTC) shares are tanking in the trade today after an update on its guidance for 2022.
The digital health care company is eyeing $1+ billion in revenues by 2027. It has reiterated its earlier guidance for 2022. Revenue is expected to land between $415 million and $420 million.
Further, adjusted EBITDA is expected to range between negative $12.5 million and negative $17.5 million.
Read full Disclosure
